Here are the DEF 14A proxy statements from Cardio Diagnostics Holdings Inc. Warrant (CDIOW) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow CDIOW and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CDIOW filings page.
Cardio Diagnostics Holdings, Inc. plans a virtual annual stockholder meeting on September 18, 2026, where holders of 2,959,469 common shares as of July 31, 2026 can vote. Stockholders will elect seven directors, approve a new share-issuance authorization, and ratify Prager Metis CPA’s LLC as auditor for 2026.
The core item is the 2026 Issuance Proposal, which would permit, in one or more non-public transactions, the future sale of up to 5.0 million shares of common stock (or equivalents) for up to $10.0 million, at discounts up to 25% below market, within three months of approval (extendable to six months with Nasdaq consent), in compliance with Nasdaq Listing Rule 5635(d). If fully used, outstanding shares could rise to about 7,959,469, an increase of approximately 169%.
The company explains this authority is intended to provide an alternative capital-raising tool alongside its existing at-the-market facility, under which it has already raised about $18.75 million and issued 2,251,181 shares. The proxy discusses potential effects of any such financing, including dilution of existing ownership, possible share-price pressure, and anti-takeover implications, and outlines the board’s governance structure, committee composition, and emerging growth company status.